Abstract
A hallmark of subclinical atherosclerosis is the accumulation of vascular smooth muscle cell (SMC)-like cells leading to intimal thickening. While medial SMCs contribute, the participation of hedgehog-responsive resident vascular stem cells (vSCs) to lesion formation remains unclear. Using transgenic eGFP mice and genetic lineage tracing of S100β vSCs in vivo, we identified S100β/Sca1 cells derived from a S100β non-SMC parent population within lesions that co-localise with smooth muscle α-actin (SMA) cells following iatrogenic flow restriction, an effect attenuated following hedgehog inhibition with the smoothened inhibitor, cyclopamine. In vitro, S100β/Sca1 cells isolated from atheroprone regions of the mouse aorta expressed hedgehog signalling components, acquired the di-methylation of histone 3 lysine 4 (H3K4me2) stable SMC epigenetic mark at the Myh11 locus and underwent myogenic differentiation in response to recombinant sonic hedgehog (SHh). Both S100β and PTCH1 cells were present in human vessels while S100β cells were enriched in arteriosclerotic lesions. Recombinant SHh promoted myogenic differentiation of human induced pluripotent stem cell-derived S100β neuroectoderm progenitors in vitro. We conclude that hedgehog-responsive S100β vSCs contribute to lesion formation and support targeting hedgehog signalling to treat subclinical arteriosclerosis.
Subject terms: Mechanisms of disease, Carotid artery disease
Introduction
Atherosclerosis is a chronic progressive inflammatory disease that leads to myocardial infarction and stroke1. Pathologic observations in humans vessels confirm that early ‘transitional’ lesions enriched with smooth muscle (SMC)-like cells called adaptive lesions are routinely present in atherosclerotic-prone regions of arteries before pathologic intimal thickening, lipid retention, and the appearance of a developed plaque2. Endothelial cell (EC) dysfunction due to disturbed blood flow is classically associated with the development of atheroprone lesions3, while the embryological origin (e.g. neuroectoderm versus mesoderm) of SMCs may also influence disease localisation and progression4. These early lesions are routinely modelled in mouse carotid arteries following flow restriction5 and can further rapidly develop into advanced atherosclerotic plaques in ApoE knockout on a Western diet6,7.
Lineage tracing and single-cell RNA sequence analysis (scRNA-seq) have provided compelling evidence in various animal models for the involvement of a rare population of (i) differentiated myosin heavy chain 11 (Myh11) medial SMC that are stem cell antigen-1 positive (Sca1+)8,9 and (ii) various adventitial and medial progenitors in progressing intimal thickening10–13. While some adventitial progenitors are derived from a parent Myh11 SMC population14, non-SMC derived SRY-related HMG-box 10 (Sox10) adventitial/medial resident multipotent vascular stem cells (vSC), glioma-associated oncogene homolog 1 (Gli), and Nestin progenitor cells have also been implicated13,15. Despite these insights, the putative role of resident vSCs that do not originate from medial Myh11+ SMCs in promoting intimal thickening remains controversial.
S100β, a member of the S100 multigenic family expressing small (9 kDa and 14 kDa) Ca2+-binding proteins of the EF-hand type, is primarily localised to astrocytes and glial cells under normal physiological conditions and is positively associated with age and various neurodegenerative and neuroinflammatory diseases16. S100β promotes intimal thickening through interaction with the receptor for advanced glycation end-products (RAGE)17 and induces migration and infiltration of inflammatory cells18,19. S100β plays a crucial role in maintaining an intermediate state of Sca1 progenitor cells following injury-induced neointimal thickening through a RAGE and stromal cell-derived factor-1 α/CXCR4 signalling mechanism20.
Hedgehog signalling (Hh) is essential for normal embryonic development and plays a pivotal role in the maintenance of adult progenitor/stem cells in tissue repair after injury21. Hh signalling is initiated upon binding of a ligand to the canonical receptors, PTCH1 and PTCH2 (Patched 1 and 2)22, which leads to disinhibition of SMO (Smoothened) and activation of a complex signalling cascade that regulates the GLI (glioma-associated oncogene homolog 1) family zinc finger transcription factors (GLI1, GLI2, and GLI3)23. GLI activators induce the transcription of Hh target genes primarily involved in cell proliferation, cell survival, and cell fate specification, including PTCH and GLI24,25. HHIP (hedgehog interacting protein) modulates hedgehog signalling activity by binding and inhibiting the action of hedgehog proteins26. Genome wide association studies (GWAS) in coronary artery disease patients have identified variants at the 14q32 HHIPL1 (Hedgehog interacting protein-like 1) that encode a paralog of HHIP27 to increase Hh signalling and regulate SMC proliferation and migration in vitro28. In atherosclerotic mice, Hh has a permissive role through increased lipid uptake by macrophages29, while global Hhipl1 deletion reduces plaque burden28. Hh signalling, especially SHh and signal peptide CUB domain and EGF like domain containing 2 (Scube2), are overexpressed in injured arteries during lesion formation after flow restriction30–32, autogenous vein grafts33, and hypoxic pulmonary arterial SMCs34. Adventitial Sca1+ cells that co-localise with SHh and Ptch135 significantly contribute to intimal thickening in vivo31,36,37 while Hh inhibition with cyclopamine or local perivascular depletion of Ptch1 attenuates intimal thickening following iatrogenic flow restriction in vivo38,39.
Given the pivotal role of Hh in the maintenance of adult progenitor/stem cells, tissue repair, and atherosclerosis21,28, we sought to determine the role of Hh-responsive S100β/Sca1 vSCs and their myogenic progeny in contributing to intimal thickening and the progression of adaptive lesions in vivo and, furthermore, whether Hh signalling directs murine S100β vSCs and hiPSC-derived S100β neuroectoderm stem cells to undergo proliferation and myogenic differentiation in vitro.
Results
Perivascular Sca1 and S100β stem vSCs are present in normal adult vessels
The presence of perivascular Sca1 and S100β vSCs was first confirmed in whole mounted vessels from Sca1-eGFP and S100β-Cre-tdT mice. A discrete number of Sca1-eGFP and S100β-tdT cells were present on collagen fibres within the adventitial layer of the thoracic aorta, when compared to wild-type (WT) controls [Supplementary Fig. 1a–d]. The cells were located predominantly at the aortic arch and at bifurcations with intercostal vessels, and their presence diminished along the descending and abdominal aorta [Supplementary Fig. 1b, c]. When the media was removed, Sca1-eGFP cells were clearly present in adventitial layer of the thoracic aorta [Supplementary Fig. 1d] and in perivascular regions of the carotid artery [Supplementary Fig. 1d].
Sca1 and S100β cells are present in intimal lesions from murine carotid arteries following iatrogenic flow restriction
The contribution of Sca1 cells to intimal medial thickening following iatrogenic flow restriction was first assessed in Sca1-eGFP transgenic mice following partial ligation of the left carotid artery (LCA). Vessels were harvested on day 3, 7, and 14 days post-ligation and paraformaldehyde fixed and paraffin-embedded cross sections were evaluated for eGFP (indicative of Sca1 expression) by confocal microscopy. Morphometric analysis confirmed that adventitial and intimal volumes increased significantly over time following ligation, without any significant change to medial volume, concomitant with a significant reduction in luminal volume after 7 and 14 days [Fig. 1a].
The number of cells within the adventitial, medial and intimal layers of the LCA did not significantly change 3 d post-ligation [Fig. 1b–d]. No Sca1- eGFP cells were visible within the medial layer of sham vessels which was populated primarily by α-smooth muscle actin (SMA) SMCs [Fig. 1e]. While a small but significant number of Sca1-eGFP cells were present within the adventitial and intimal layers of sham vessels, the fraction of Sca1-eGFP cells significantly increased within the intimal layer 3 d post-ligation [Fig. 1e, f]. Immunohistochemical analysis using anti-eGFP confirmed the presence of intimal Sca1-eGFP cells in ligated vessels [Fig. 1e] and further demonstrated that intimal Sca1-GFP cells co-express PECAM-1/CD31 and endothelial cell nitric oxide (eNOS) [Fig. 1e]. Moreover, there was also a notable increase in the expression of the pro-apoptotic protein, Bax within the intimal, adventitial and medial layer of the LCA and the medial layer of the RCA 3 d post-ligation [Fig. 1g, h], consistent with disturbed flow- and strain -induced apoptosis40.
While the majority of Sca1-eGFP cells were present in the adventitial and intimal layers of sham-operated vessels, a small fraction were also visible within the medial layer after 7, 14, and 21d [Fig. 2a, b, g and Supplementary Fig. 2a, b]. Upon injury, there was a notable appearance of Sca1-eGFP cells within the expanding intimal layer of ligated vessels after 7, 14, and 21d [Fig. 2a, b, d, g] that coincided with an increase in the number of cells [Fig. 2c] and the volume of the neointimal layer [Fig. 1a]. Cumulative analysis revealed that there was a significant increase in the fraction of Sca1-eGFP cells within neointimal layers after 7 and 14 and 21d, respectively, when compared to sham vessels or contralateral RCA [Fig. 2d, h]. The majority of Sca1 cells within these lesions co-localised with SMA+ cells [Fig. 2e, f, Supplementary Fig. 3a].
The contribution of S100β vSC to intimal thickening following iatrogenic flow restriction was also assessed in S100β-eGFP transgenic mice. While the majority of S100β-eGFP cells were present in the adventitial layer of sham-operated vessels and the contralateral RCA, a small fraction were also present within the medial layer after 21d [Supplementary Fig. 2a, c, Fig. 2g, h]. In contrast, no intimal S100β-eGFP cells were present in sham vessels or the contralateral RCA [Supplementary Fig. 2a, c–e]. Upon injury, the fraction of S100β-eGFP cells within lesions significantly increased when compared to sham vessels and the contralateral RCA [Supplementary Fig. 2d, e and Fig. 2g, h]. Importantly, the number of double positive Sca1/S100β cells increased within the neointimal layers of ligated vessels compared to the sham [Supplementary Fig. 2d, e] and contralateral RCA control [Fig. 2g, h]. Similarly, the number of double positive S100β/SMA cells increased within lesions compared to the contralateral RCA [Fig. 2i, j]. Taken together, these data suggest double positive Sca1/S100β cells populate vascular lesions following iatrogenic injury in vivo.
Lineage tracing analysis of marked perivascular S100β cells iatrogenic flow restriction
In order to determine the source of intimal double positive Sca1/S100β cells following flow restriction, lineage tracing analysis was performed using transgenic S100β-eGFP-CreERT2-Rosa26-tdTomato reporter mice [Supplementary Fig. 4a]. As cre-mediated recombination results in a permanent heritable change in a cell’s genome, these cells and their progeny remain tdTomato (tdT) positive. The animals were treated with tamoxifen (Tm) for 7 days to induce nuclear translocation of CreER(Tm) and subsequent recombination to indelibly mark S100β cells with red fluorescent tdT seven days before ligation was performed [Supplementary Fig. 4b]. Only S100β cells present during the period of Tm treatment and their subsequent progeny following injury are marked with tdT. The tissue specificity and recombination efficiency of the Tm-induced Cre activity was confirmed in bone marrow smears and neuronal tissue from S100β-eGFP-CreERT2-Rosa26-tdTomato mice. Treatment with Tm resulted in Cre-mediated recombination and expression of S100β- tdT in >90% of neuronal cells of the carotid sinus nerve (Hering’s nerve) without any S100β-tdT cells observed in the bone marrow smears [Supplementary Fig. 4c]. The neuronal staining was confirmed by immunohistochemical analysis of S100β expression using both anti-S100β and anti-tdT antibodies (data not shown).
Morphometric analysis of the S100β-eGFP-creER2-Rosa26tdT mice confirmed significant intimal thickening in transgenic mice following ligation injury when compared to the sham LCA and contralateral RCA [Fig. 3a–c]. Treatment of S100β-eGFP-creER2-Rosa26tdT transgenic mice with tamoxifen indelibly marked S100β cells (S100β-tdT) within the adventitial layer of the sham LCA prior to flow restriction [Fig. 3d]. No cells are marked when these double transgenic mice were treated with the vehicle control (corn oil) [Fig. 3d]. Importantly, no S100β-tdT cells were observed in the intimal (EC) or medial (SMC) layers of these sham vessels following tamoxifen treatment [Fig. 3d]. However, following ligation, there was a striking increase in the number of S100β-tdT marked cells within the medial and intimal layers of the ligated LCA, compared to sham controls [Fig. 3e, f]. In order to rule out the possibility that Tm treatment continues to label a significant number of cells for weeks after last Tm treatment41, we confirmed that the fraction of S100β-tdT marked cells remained significantly higher in the neointima of LCA four weeks after the last Tm injection when compared to the RCA [Supplementary Fig. 4d, e]. Moreover, the fraction of S100β-tdT marked cells within the LCA adventitial, medial and intimal layers of ligated vessels after one and four weeks from the last Tm injection was of a similar magnitude [Supplementary Fig. 4f].
When S100β-tdT marked cells were evaluated for co-expression of Sca1 and SMA by immunohistochemistry using anti-Sca1, anti-SMA and anti-tdT antibodies, S100β-tdT marked cells co-localised with Sca1 cells in the adventitial and medial layers (but not the intimal layer) of the control contralateral RCA before injury [Supplementary Fig. 3d, Fig. 3g]. There was a notable increase in the number of double stained Sca1/S100β-tdT cells in the media and neointima of the LCA compared to the contralateral RCA [Fig. 3g] and the sham LCA control [Supplementary Fig. 3b] in double stained SMA/S100β-tdT cells within the neointima and media compared to the sham control [Supplementary Fig. 3c]. Cumulative analysis confirmed both a significant increase in the fraction of S100β-tdT cells [Fig. 3h] and the fraction of double stained S100β/Sca1 cells [Fig. 3i] within the LCA medial and intimal layers compared to the contralateral RCA control. Moreover, the majority of Sca1 cells within ligated vessels were S100β-tdT cells [Fig. 3j]. Since intimal and medial cells are not marked with tdT prior to injury, these data suggest that these cells are derived from a non-SMC S100β parent population following flow restriction. Moreover, the majority of intimal Sca1 cells are derived from an S100β parent population.
Hedgehog signalling components control intimal thickening following iatrogenic flow restriction
The effect of systemic administration of the Hedgehog inhibitor cyclopamine (10 mg/kg, IP, every other day) on neointimal thickening and the accumulation of Sca1-eGFP cells was evaluated. 2-hydroxypropyl-β-cyclodextrin (HβCD) was used as a vehicle control. Vessels were harvested 7 and 14 d post-ligation and morphometric analysis was performed. Whole-vessel Gli1 and Gli2 mRNA levels were significantly elevated in ligated vessels treated with HβCD when compared to sham controls (Gli1: 6.1 ± 1.3 after 3 d; Gli2:8.1 ± 0.9 fold after 14 d, p ≤ 0.05 n = 4), an effect that was significantly reduced following cyclopamine treatment (Gli2: 3.2 ± 0.3 fold, n = 4, p ≤ 0.05). Immunohistochemical analysis revealed that the Hh receptor, Ptch1, was up-regulated in LCA following injury concomitant with enhanced Gli2 expression in LCA when compared to sham vessels [Fig. 4a]. Gli2 co-localised with Sca1-eGFP expressing cells and was markedly increased in ligated vessels treated with vehicle (HβCD) when compared to sham-operated vessels, especially in the neointima and media of the LCA, an effect that was attenuated following Hh inhibition [Fig. 4a]. Cyclopamine treatment significantly reduced the fraction of Sca1-eGFP expressing cells [Fig. 4b, c] concomitant with reduced intimal thickening 7 d and 14 d post-ligation [Fig. 4d, g]. Collectively, these data suggest that intimal thickening is attenuated by systemic administration of the smoothened inhibitor, cyclopamine, concomitant with a reduction in the accumulation of Gli2/Sca1 Hh-responsive cells within the intimal and medial layers.
Isolation and characterisation of resident S100β/Sca1 vascular stem cells from murine aorta
The expression of SMC differentiation markers genes, Myh11 and Cnn1 was enriched in medial segments from both atheroprone aortic arch (AA) and atheroresistant thoracic/abdominal aorta (TA) regions of the mouse aorta, when compared to NE-4C cells and immortalised MOVAS mSMCs in culture [Fig. 5a]. The level of S100β and Sox10 expression, both markers of resident vascular stem cells12,42, was then assessed in AA and TA regions, with or without the adventitia [Fig. 5b, c]. There was significant enrichment of both S100β and Sox10 in the AA when compared to the TA. Moreover, the levels were significantly enriched within the adventitia since its removal resulted in a dramatic reduction in the expression of both transcripts. Nevertheless, medial expression of both genes was still observed in the AA region [Fig. 5b, c].
Resident vascular stem cells (vSCs) were subsequently isolated from mouse aortic arch (AA) and thoracic aorta (TA) by enzymatic digestion and sequential plating, and were characterised by flow cytometry, immunocytochemistry, and gene expression for both stem cell markers and SMC differentiation markers. Flow cytometric analysis confirmed that the cells were Sca1 and S100β positive when compared to Sca1 and S100β positive control cell lines (i.e. C3H 10T1/2 and NE-4C, respectively) [Fig. 5d]. The vSCs did not enrich for Myh11 or Cnn1 transcripts when compared to fresh aortic tissue [Fig. 5e, f] or express these proteins [Fig. 5g, h] but exhibited greater teleomere length as a measure of stemness when compared to freshly isolated aortic SMC and to the immortalised MOVAS SMCs in culture [Fig. 5i]. Immunocytochemical analysis revealed that vSCs from both AA and TA regions were Sca1 positive and expressed neuroectodermal markers S100β, Sox10, Sox17, and Nestin but were negative for SMC differentiation markers Cnn1 and Myh11 [Fig. 5g, h]. The vSCs were enriched for neuroectodermal marker genes S100β, Sox10, and Nestin [Supplementary Fig. 5a–c], but not for mesoderm markers Kdr, Pax1 and Tbx6 [Supplementary Fig. 5d–f], when compared to SMCs and NE-4 cells in culture. Collectively, these data indicate that neuroectodermal S100β/Sca1 cells are primarily located within the adventitial perivascular region of atheroprone regions of the mouse aorta and can be isolated and expanded in vitro to retain these phenotypic markers.
Hedgehog signalling promotes myogenic differentiation of resident murine S100β/Sca1 vascular stem cells in vitro
The functional effect of sonic hedgehog (SHh) signalling on the growth and myogenic differentiation of vSCs was evaluated in vitro using multipotent Sca1/S100β cells isolated from mouse aorta. Whole-vessel Gli1 mRNA levels increased over time following ligation [Supplementary Fig. 6c]. Treatment of vSCs isolated from AA and TA with recombinant SHh (rSHh, 0.5 µg/ml, 24 h) promoted Hh signalling by increasing Hh target gene mRNA levels (Gli1, Gli2 and Ptch1), an effect blocked following pre-treatment with cyclopamine [Fig. 5j, k and Supplementary Fig. 6a, b]. Concurrent treatment of cells with rSHh for 7 days resulted in a significant increase in SMC differentiation marker gene expression (Cnn1 and Myh11), an effect attenuated by pre-treatment of cells with cyclopamine [Fig. 5j, k]. SHh treatment also significantly increased the growth of AA vSCs after 7 days, an effect attenuated by pre-treatment with cyclopamine [Supplementary Fig. 6d].
The level of enrichment of the SMC specific epigenetic histone mark, di-methylation of lysine 4 on histone H3 (H3K4me2) and the repressor mark, tri-methylation of lysine 27 on histone H3 (H3K27me3) at the Myh11 locus was assessed using chromatin immunoprecipitation (ChIP) assays before and after rSHh treatment. Freshly isolated differentiated aortic medial SMC and murine embryonic stem cells (mESCs) were used as positive/negative controls for each mark and were markedly enriched for H3K4me2 and H3K27me3 at the Myh11 promoter, respectively [Fig. 5l–n]. In contrast to medial SMCs, AA vSCs were enriched for H3K27me3 but lacked enrichment of H3K4me2 at this locus. Treatment with recombinant SHh (rSHh, 0.5 µg/ml, 7 d) increased the enrichment levels of the H3K4me2 mark while concurrently decreasing the enrichment of the H3K27me3 mark, an effect attenuated by cyclopamine [Fig. 5l–n]. Finally, SHh treatment significantly increased the fraction of Cnn1+ and Myh11+ cells in AA vSCs, an effect attenuated by pre-treatment with cyclopamine [Fig. 5o, p].
S100β cells populate human arteriosclerotic lesions
The expression of SMA, S100β, and the hedgehog receptor, PTCH1, was determined by immunofluorescence staining in normal and arteriosclerotic human aortic sections. The expression of SMA was abundant in the medial layers of both normal and arteriosclerotic vessels while reduced within the neointima [Fig. 6a]. The expression of S100β was confined to the adventitial layer of normal vessels but was significantly enhanced within the adventitial and intimal layers of arteriosclerotic sections [Fig. 6a]. The expression of PTCH1 was confined to the adventitial layers of normal vessels but was also sparsely expressed in the medial and intimal layers of arteriosclerotic sections [Fig. 6a].
Hedgehog signalling promotes myogenic differentiation of human induced pluripotent stem cell (HiPSC)-derived neuroectodermal S100β vascular stem cells in vitro
To address whether human neuroectoderm S100β progenitors (NEPs) respond to hSHh by undergoing myogenic differentiation, S100β NEPs were isolated from human induced pluripotent stem cells (HiPSC) using a chemically defined protocol43. Human iPSCs enriched for Oct4 were treated with neuroectodermal inductive stimuli (FGF2 and the selective inhibitor of ALK5, SB413642) for 7 days [Fig. 6b] and expressed S100β but not SMC differentiation markers CNN1 and MYH11 [Fig. 6b]. Treatment of NEPs with myogenic media supplemented with TGF-β1/PDGF-BB significantly increased the fraction of CNN1 and MYH11 cells after a further 12 d in culture, while concomitantly decreasing the number of S100β cells [Fig. 6c]. The levels of S100β, CNN1, and MYH11 transcripts mirrored the changes in protein, where NEP-derived SMCs became significantly enriched for CNN1 and MYH11 following TGF-β1/PDGF-BB treatment as they diminish their expression of S100β [Fig. 6d]. Treatment of NEPs with rSHh (1.0 µg/ml) for 12 d resulted in a significant increase in CNN1 and MYH11 mRNA levels, an effect attenuated by cyclopamine [Fig. 6e, f], concomitant with an increase in the number of CNN1-positive cells [Fig. 6g]. SHh treatment also significantly increased the growth of S100β NEPs after 12 days in culture, an effect attenuated by pre-treatment with cyclopamine [Supplementary Fig. 6e].
Discussion
In this study, we used transgenic mice and genetic lineage tracing approaches to delineate the involvement of Hh-responsive S100β resident vSCs in progressing neointima formation following flow restriction. Our findings indicate that intimal thickening involves significant accumulation of Hh-responsive S100β-derived progeny. Elucidation of this new cellular S100β source for generating SMC-like cells following injury expands our current understanding of vascular pathology and may represent an important therapeutic strategy for combating subclinical atherosclerosis.
SMC-like cells within neointimal lesions reportedly are monoclonal/oligoclonal in origin arising from the expansion of a pre-existing resident clonal population of cells44–47. Despite extensive research, their origin has remained controversial48. As a general rule, SMCs are purported to switch from a contractile phenotype to a less mature synthetic phenotype following vascular injury resulting in the loss of expression of SMC differentiation contractile markers, increased proliferation, and the synthesis and release of pro-inflammatory cytokines, chemotaxis-associated molecules, and growth factors49. However, whether these clonal progeny within lesions are derived primarily from differentiated medial SMCs8,9,49, endothelial cells10,50, and/or resident vSCs10–13 remains unclear. Over the last decade, vascular SMC lineage tracing studies have provided compelling evidence of a significant role for pre-existing medial SMCs in vascular pathologies8,51–53. Single-cell RNA sequence analysis (scRNA-seq) further identified a rare Sca1+ Myh11-Cre marked SMC subpopulation that gives rise to functionally distinct neointimal cells during lesion progression in mice8,9. However, although the Myh11-CreERT2 transgene was originally deemed specific for vascular SMC54, data indicating expression of this and other ‘SMC differentiation genes’ in non-SMC populations has recently emerged55–57 raising the possibility that other resident cells may be inadvertently marked and contribute to lesion formation. Myh11-CreER SMC lineage tracing studies have also demonstrated that the fraction of SMCs originating from pre-existing SMCs may be considerably smaller after severe transmural injury in mice further suggesting a contributory role for cells other than medial SMCs58.
In this study, we provide genetic evidence that vascular lesions contain an abundance of dual labelled Hh-responsive S100β/Sca1 vSCs derived from a non-SMC perivascular and/or medial S100β parent population. Notwithstanding the fact that Sca1 cells are present in bone marrow59, bone marrow cells were not marked using the S100β-CreERT2-tdT. It is therefore most likely that Sca1/S100β cells marked with S100β-CreERT2-tdT within lesions were locally derived47. S100β cells predominate within the adventitial layer of healthy vessels (murine and human) since removal of the adventitia dramatically reduced aortic S100β transcript levels in mice. Nevertheless, a small fraction of S100β/Sca1+ cells are present in medial layer of normal vessels and could be successfully isolated from aortic medial segments following enzymatic digestion and sequential plating in vitro. Indeed, previous studies using in situ immunohistochemical analysis and scRNA-seq also confirms the presence of a sparse Sox10/S100β cell population within the media, in addition to the adventitia9,60,61. However, these enrichment levels were minimal compared to an S100β+ neuronal cell and vascular adventitial ‘fibroblast-like cell’ phenotypes within the vessel wall, supporting the contention that a perivascular adventitial S100β cell may be the predominant source of S100β within the vessel wall. Similarly, a discrete population of immature medial cells expressing CD146 that emerge during embryonic development may also contribute to neointimal formation in response to injury58. Whether these CD146 immature SMC progenitors are also S100β/Sca1 remains unclear although S100β vSCs derived from rat and murine aortic explants express CD14612,42. In the future, it will be important to determine whether medial S100β vSCs differ from CD14658 and Myh11-CreER Sca1 cells9 in their propensity to modulate different phenotypes and undergo clonal expansion using various injury models.
Adventitial progenitors have long been implicated in the progression of neointimal lesions following various vascular injuries62,63. However, in the absence of Sca1 or c-kit+ stem cell lineage tracing experiments in vivo, the hypothesis of a regenerative function for adventitial Sca1 or c-kit+ vSCs in lesion formation has been difficult to prove until recently. While perivascular cells must first traverse the internal and external elastic lamina to accumulate within the intima following injury64, disruption of the elastic lamellae and flow-dependent enlargement of fenestrae can facilitate such migration65,66,67. Cell fate mapping studies have now clarified the role for adventitial PDGFRα Sca1 progenitors in lesion progression following severe injury11 while c-kit progenitors minimally facilitate endothelial regeneration or SMC differentiation to SMCs68. As Sca1-CreER marked cells were not present in vascular lesions following wire-induced injury11, the origin of Sca1 neointimal cells following flow restriction in the current study is unlikely to be from a Sca1 parent population despite expressing Sca1 (albeit using a different injury model). Indeed, the percentage of perivascular S100β-CreER marked cells that were Sca1+ in normal vessels was <50% indicating that a Sca1neg/S100βpos population might be responsible. In this context, S100β has been shown to maintain an intermediate state of Sca1 progenitor cells following lesion formation20. Alternatively, this residual Sca1pos/S100βneg population of adventitial Sca1 cells might represent Sca1 cells derived from differentiated Myh11-CreER SMCs that expand in number following injury and contribute to adventitial remodelling14 and lesion formation9. While Sca1/S100β cells were predominantly found in the developing intimal layer after 7, 14, and 21 days, these cells were also present in the medial layer following injury. In agreement with previous studies demonstrating significant apoptosis of medial SMCs following flow restriction69, the appearance of medial Sca1/S100β cells marked with S100β-CreERT2-tdT following early expression of the pro-apoptotic protein Bax within the media is consistent with regeneration of medial SMCs following injury.
Previous lineage tracing studies have also implicated endothelial cells (EC) that undergo endothelial-to-mesenchymal transition (EndMT) to SMC-like cells as contributing to neointimal formation during vein graft remodelling10,50. EndMT promotes neointimal hyperplasia and induces atherogenic differentiation of EC70. In the current study, EC were not marked with S100β-CreERT2-tdT prior to flow restriction suggesting that the S100β-CreERT2-tdT marked cells within lesions do not originate from an EC parent population. These apparent differences may result from the use of different models of vascular injury where vein graft and atherosclerosis models involve different biomechanical stimuli and/or a different inflammatory environments compared to the flow restriction model50,71. While EC did not contribute to neointimal formation in developed lesions, a potential role for adluminal Sca1 cells in regenerating the endothelium following ligation was observed. As flow restriction leading to alterations in shear stress and cyclic strain is strongly associated with increased endothelial cell apoptosis in vitro72 and in vivo73, significant Bax expression at the adluminal surface was observed after flow restriction. Bcl-2/Bax ratios are an important rheostat to determine the incidence of apoptosis in general and increases in Bax expression have been widely reported and validated using the TUNNEL assay to indicate apoptosis of endothelial cells in vitro in response to low shear stress (LSS)74 and in vivo following carotid artery ligation in wild-type mice75 or following flow perturbation in ApoE deficient mice76. The increase in Bax expression concomitant with an increase in the number of Sca1 cells that maintain a CD31 and eNOS endothelial cell phenotype at the adluminal surface is consistent with the appearance of new endothelial cells in the injured vessel that are derived from the proliferation of adluminal Sca1 cells. Indeed, recent cell fate mapping studies using Sca1-CreERT2-tdT mice have since confirmed this observation by demonstrating expansion of Sca1-CreERT marked cells in the intimal layer that maintain CDH5 endothelial cell fate following injury11.
There are many potential reasons for the different outcomes of lineage tracing studies that addressed the origin of lesional SMC-like cells including technical considerations around fixation, tissue preservation, brightness and contrast settings for image acquisition, autofluorescent material such as lipofuscin and single-cell resolution77. Another important reason may involve the use of tamoxifen (Tm) in time-sensitive Tm-dependent Cre-LoxP models. Tm-induced Cre recombinase has been shown to indelibly mark cells up to 4 weeks after the last Tm injection thereby potentially confounding the interpretation of many previous studies41. In this context, we found that the fraction of S100β-CreER (tdT) marked cells within the various compartments of ligated vessels four weeks after the last Tm injection was similar to that observed after one week, indicating that, at least in our hands, medial SMC that might undergo de-differentiation and acquire the S100β promoter are not being inadvertently marked after injury.
Several GWAS studies have implicated HHIPL1 at the chromosome 14q32 CAD locus27,78 and identified it as a secreted Hh signaling protein that modulates atherosclerosis-relevant vascular phenotypes28. Here we provide direct evidence that inhibition of Hh signalling controls neointimal thickening following flow restriction by attenuating the volume and accumulation of Sca1 cells within lesions. Furthermore, Hh signalling directly promotes Sca1/S100β cells from mouse and S100β neuroectoderm stem cells derived from human induced pluripotent stem cells (HiPSC) to undergo growth and myogenic differentiation to SMC-like cells in vitro. The possibility that Hh-responsive S100β/Sca1 cells isolated from murine AA and TA regions are derived from a Myh11 medial SMC population was ruled out by examining the H3K4me2 epigenetic profile of S100β/Sca1 cells at the Myh11 locus, which is preserved during SMC phenotypic modulation in vitro and in vivo following injury79. Hh-responsive S100β/Sca1 vSCs do not have this SMC histone mark and only become enriched following myogenic differentiation to SMC-like cells, an effect attenuated by the Hh inhibitor, cylopamine. The accumulation of Sca1/S100β cells within lesions may be due, in part, to asymmetric division of Sca1/S100β progenitor stem cells (from the adventitia and/or media) and subsequent proliferation and migration of their partially differentiated myogenic progeny to the intima. Indeed, SHh promotes Sca1/S100β growth and the proliferation of modulated, partially differentiated SMCs in vitro32. Moreover, previous studies have shown that it is a Sca1 adventitial population in particular that proliferate following injury using immunohistochemical co-staining with Ki-6731. This is not surprising as adventitial Sca1 stem cells co-localise with SHh and its receptor, Ptch135 while several previous studies support a role for Hh signalling in vascular lesion formation in mice29,38,39. It appears the Yes-Associated Protein (YAP) is required for incorporation and expansion of Sca1-derived neointimal cells following injury11 where the Hh pathway reportedly acts upstream of the Hippo pathway to regulate stem cell maintenance80. Indeed, our data suggest S100β cells are also present in normal vessels within the adventitial layer where Hh components reside81,82. In arteriosclerotic lesions, S100β expression is exaggerated within the neointimal layer with sparse staining for PTCH1 present. As S100β NEP-derived SMCs are considered crucial to the generation of SMC in vascular lesions within atheroprone regions of the murine vasculature4,43, it is tempting to speculate that Hh-responsive S100β-derived SMC-like progeny may also play a pivotal role in lesion formation in humans. Future studies that address the interactions between Hippo pathway and Hh may yield therapeutic strategies aimed at interfering with YAP activity through inhibition of hedgehog pathway, which downregulates the YAP protein83,84.
In conclusion, the identification of a population of S100β/Sca1 cells within vascular lesions that are derived from a non-SMC S100β parent population is novel and highlights these cells as an important source for intimal thickening following injury. Furthermore, the role of SHh in mediating this process expands our understanding of the mechanisms contributing to the progression of vascular lesions. While Hh signalling has previously been implicated in the development of vascular lesions through modulation of a differentiated SMC phenotype28, our study further suggests that Hh signalling may also control myogenic differentiation and accumulation S100β/Sca1-derived SMC-like progeny within vascular lesions. While hedgehog signalling appears critical, further research is required to investigate the precise mechanisms driving migration, proliferation and differentiation of stem cells during lesion formation. It is possible that SMC-like cells within lesions comprise several different stages of the myogenic, osteogenic, and myeloid differentiation of various stem cells and hence display a variety of divergent phenotypes. The elucidation of these mechanisms will provide vital information needed for the development of more efficient and novel therapies for vascular proliferative diseases. Our results provide a potential strategy for the treatment of atherosclerosis by combating cell migration and asymmetric differentiation of a perivascular-derived S100β parent vSC population.
Methods
Mice breeding and genotyping
All procedures were approved by the University of Rochester Animal Care Committee in accordance with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals. Sca1-eGFP transgenic mice were obtained from JAX labs; Stock #012643, strain name B6.Cg.Tg(Ly6a-EGFP)G5Dzk/j. These transgenic mice have an enhanced green fluorescent protein (eGFP) under the control of murine lymphocyte antigen 6 complex, locus A (Ly6a) promoter. Hemizygous Ly6a-GFP mice are viable, fertile, normal in size and do not display any gross physical or behavioural abnormalities85.
S100β-EGFP/Cre/ERT2 transgenic mice (JAX Labs, stock #014160, strain name B6;DBA-Tg(S100β-EGFP/cre/ERT2)22Amc/j) express the eGFPCreERT2 (Enhanced Green Fluorescent Protein and tamoxifen inducible cre recombinase/ESR1) fusion gene under the direction of the mouse S100β promoter. Ai9 mice (Jax Labs, stock #007909, strain name B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze /J) express robust tdTomato fluorescence following Cre-mediated LoxP recombination. For lineage tracing experiments S100β-eGFP/Cre/ERT2–dTomato double transgenic mice of both genders were generated by crossing S100β-eGFP/CreERT2 mice with Ai9 reporter mice. The tdTomato transgene expression pattern corresponds to genomic marked S100β cells, and the eGFP transgene expression pattern corresponds to constitutive expression of S100β. Mice were genotyped using genomic DNA prepared from tail samples. All male and female mice were included in the study and were 8–10 weeks old.
Tamoxifen-induced genetic lineage tracing
S100β-CreER-Rosa26tdT mice (average weight 20 g, 6–8 weeks old) were injected IP with tamoxifen (Tm) dissolved in corn oil at 75 mg/kg for 5 consecutive days. Carotid artery ligation (partial, or complete), or sham operation, was performed at 1 week or 4 weeks after the last injection of Tm. At the indicated time post-ligation or sham operation, anesthetized mice were perfusion fixed and carotid arteries harvested for analysis.
Carotid artery ligation
Ligation of the left common carotid artery was performed essentially as described previously38 1 and 4 weeks after Tm-induced cre-recombination, in male and female S100β-eGFP/Cre/ERT2–dTomato double transgenic mice. Prior to surgery mice received a single dose of Buprenorphine SR (sustained release) analgesia (0.5–1.0 mg/kg SQ) (and every 72 h thereafter as needed). The animal was clipped and the surgical site prepped using betadine solution and alcohol. A midline cervical incision was made. For partial carotid artery ligation, with the aid of a dissecting microscope, the left external and internal carotid arterial branches were isolated and ligated with 6–0 silk suture reducing left carotid blood flow to flow via the patent occipital artery. The neck incision (2 layers, muscle and skin) was sutured closed. Partial ligation of the left carotid artery in this manner resulted in a decrease (∼80%) in blood flow, leaving an intact endothelial monolayer. Buprenorphine was administered at least once post-op 6–12 h. For complete ligation, the left common carotid was isolated and ligated just beneath the bifurcation with 6–0 silk suture. In sham surgery group, carotid was similarly manipulated but not ligated. The neck incision (2 layers, muscle and skin) was sutured closed and the animal allowed recover under observation. After 3, 7, 14, and 21 days, mice were perfused with 4% PFA via the left ventricle for 10 min, and carotid arteries were harvested for analysis.
Cyclopamine treatment
Sca1-eGFP mice were treated with the smoothened inhibitor, cyclopamine, or the vehicle 2-hydropropyl-β-cyclodextrin (HβCD) (Sigma–Aldrich) alone as a control, (essentially as described previously)86. Mice were injected (250 μl max volume) intraperitoneally (IP) 1 day before ligation, then every other day after ligation at a dose of 10 mg/kg Cyclopamine (Sigma–Aldrich) dissolved in a solution of 45% (w/v) HβCD. There was no effect of cyclopamine treatment on mouse body weight, compared to the HβCD vehicle control group (data not shown).
Histomorphometry
At specified times post-ligation, mice were anesthetized (ketamine/xylazine) and perfusion fixed with 4% paraformaldehyde in sodium phosphate buffer (pH 7.0). Fixed carotids were embedded in paraffin for sectioning. Starting at the carotid bifurcation landmark (single lumen) a series of cross sections (10 × 5 μm) were made, every 200 μm through 2 mm length of carotid artery. Cross sections were de-paraffinized, rehydrated in graded alcohols and stained with Verhoeff-Van Gieson stain for elastic laminae and imaged using a Nikon TE300 microscope equipped with a Spot RT digital camera (Diagnostic Instruments). Digitized images were analyzed using SPOT Advanced imaging software. Assuming a circular structure in vivo, the circumference of the lumen was used to calculate the lumen area, the intimal area was defined by the luminal surface and internal elastic lamina (IEL), the medial area was defined by the IEL and external elastic lamina (EEL), and the adventitial area was the area between the EEL and the outer edge, essentially as described by us previously38.
Haematoxylin and eosin staining of tissue
For human artery cross sections, slides were placed in ice-cold acetone and held at −20 °C for 15 min. They were then washed 3 × PBS before immersion in Harris Haematoxylin at room temperature for 8 min. Slides were processed by sequential washing—in distilled water for 5 min; 1% acid alcohol for 30 sec; 0.1% sodium bicarbonate for 1 min, and 95% ethanol. Slides were then washed in Eosin for 1 min, 75% ethanol for 3 min, 95% ethanol for 3 min, and 100% ethanol for 3 min before being submerged in Histoclear for 3 min and permanently mounted using three drops of DPX, cleaned with 100% ethanol before analysis.
For murine vessels, paraffin rehydration was conducted at room temperature by immersing the slides in xylene for 20 min. The slides were then immersed in the following gradients of ethanol for 5 min, respectively: 100, 90, 70, and 50% ethanol. The slides were then rinsed in distilled H2O2 before washing in 1x PBS for 10 min. The slides were stored in 1× PBS until ready when they were immersed in Harris Haematoxylin at room temperature for 8 min.
S100β+ cells were identified as either “genomically marked” red tdTomato expressing cells or “currently expressing” green fluorescent protein (eGFP) cells visualized in de-paraffinized S100β‐eGFP/Cre/ERT2–dTomato mouse carotid cross sections mounted with Sigma Fluoroshield with DAPI, using an FV1000 Olympus or a Nikon A1R HD laser scanning confocal microscope. Numbers of red or green fluorescent cells and DAPI nuclei (blue) in carotid cross section images from different experimental groups were either analyzed by Fiji ImageJ software in each vessel compartment using a grid system.
Whole mount histochemical analysis
Briefly, arteries harvested from transgenic mice were washed in PBS before transfer to 10% neutral buffered formalin and incubated at 4 °C overnight. The tissue was rinsed 3 × PBS before mounting on histology slides using DAPI containing fluoroshield (Sigma). The whole tissue was then imaged using a Nikon Eclipse TS100 inverted microscope, EXFO X-Cite™ 120 fluorescence system and assessed using SPOT imaging software.
Immunofluorescent staining of tissues
Immunostaining essentially as previously described38. Carotid artery cryosections were air-dried for 1 h at room temperature, followed by incubation with blocking buffer (5% donkey serum, 0.1% Triton X-100 in PBS) for 30 min at room temperature and then incubated with primary antibody overnight at 4 °C in antibody solution (2.5% BSA, 0.3 M Glycine and 1% Tween in DPBS). Murine and human arterial sections were stained with primary antibodies [Supplementary Table I]. Isotype IgG control and secondary antibody only controls were performed. For antigen retrieval, slides were brought to a boil in 10 mM sodium citrate (pH 6.0) then maintained at a sub-boiling temperature for 10 min. Slides were cooled on the bench-top for 30 min then washed in deionized water (3 × 5 min) each before being washed in PBS (3 × 5 min). The antigen retrieval protocol diminishes endogenous eGFP and tdT tomato transgene signals. Therefore, those sections were co-stained with anti-eGFP antibody and anti-Td tomato antibody [Supplementary Table I].
For immunofluorescence staining, 5 consecutive images were obtained and processed using ImageJ software™ to analyze the collected images. Mouse carotid artery cross sections were mounted with fluoroshield with DAPI and analyzed using an FV1000 Olympus or a Nikon A1R HD laser scanning confocal microscope. Images were merged using the Image color-merge channels function. Merged signals and split channels were used to delineate the signals at single-cell resolution. Settings were fixed at the beginning of both acquisition and analysis steps and were unchanged. Brightness and contrast were lightly adjusted after merging.
Immunocytofluorescent staining of cells
Cells seeded onto UV sterilized coverslips were fixed with 3.7% formaldehyde, (15 min, RT). If cells required permeabilization for the detection of intracellular antigens, cells were incubated in 0.025% Triton X-100 PBS (room temp, 15 min). All coverslips were blocked (1 h, RT) using 5% BSA, 0.3 M Glycine, 1% Tween PBS solution (1 h, RT). Cells were incubated with primary antibodies overnight at 4 °C [Supplemental Table II], then washed twice with PBS to remove any unbound primary antibody before being incubated (1 h, RT) with the recommended concentration of fluorochrome-conjugated secondary antibodies diluted in blocking buffer [Supplementary Table II]. Following 2× wash in PBS, cell nuclei were stained using DAPI: PBS (dilution 1:1000) (15 min, RT). For each primary and secondary antibody used, a secondary control and an IgG isotype control was performed to assess nonspecific binding. An Olympus CK30 microscope and FCell™ software was used to capture images. Images were analyzed using ImageJ software as described above. Settings were fixed at the beginning of both acquisition and analysis steps and were unchanged. Brightness and contrast were lightly adjusted after merging.
Cell culture and harvesting
Murine aortic SMCs (MOVAS (ATCC® CRL-2797™) were cultured in Dulbeco’s Modified Eagles growth medium (DMEM) supplemented with Fetal Bovine Serum (10%), L-glutamine (2 mM, Gibco), and Penicillin-Streptomycin (100 U/mL, Gibco). Murine neuroectodermal stem cells (mNE-4Cs, ATCC® CRL-2925™) were grown in Eagle’s Minimum Essential Medium supplemented with Fetal Bovine Serum (10%), L-glutamine (2 mM, Gibco) and Penicillin-Streptomycin (100 U/mL, Gibco) using Poly-L-Lysine coated plates (15 μg/ml). Murine embryonic C3H 10T1/2 cells (ATCC® CRL-226™) were grown in Eagle’s Basal medium supplemented with heat-inactivated fetal bovine serum to a final concentration of 10% and 2mM L-glutamine. Murine embryonic stem cells (mESCs) ES-D3 [D3] (ATCC® CRL-1934™) were maintained in culture in Mouse ES-Cell Basal Medium (ATCC SCRR-2011) supplemented with 2-mercaptoethanol (0.1 mM) and 15% ES-Cell Qualified FBS (ATCC SCRR-30-2020) and a 1000 U/mL mouse leukemia inhibitory factor (LIF) (Millipore Cat. No. ESG1107). Murine vSCs from AA and TA regions of the mouse aorta were grown in DMEM media supplemented with chick embryo extract (2%), FBS embryonic qualified (1%, ATCC), B-27 Supplement, serum free, N-2 Supplement (Cell Therapy Systems), recombinant mouse bFGF (0.02 μg/mL), 2-Mercaptoethanol (50 nM), retinoic acid (100 nM), Penicillin-Streptomycin (100 U/mL, Gibco) (MM).
Isolation of S100β/Sca1 murine resident vascular stem cells (vSCs)
Using an optimised enzymatic cell dissociation technique protocol vSCs from both atheroprone (aortic arch—neuroectodermal, NE), and atheroresistant (thoracic aorta—paraxial mesodermal, PM) regions of the murine aorta were isolated using sequential seeding on adherent and non-adherent plates. Mouse thoracic aortas (4 at a time) were harvested and placed in cold Hank’s solution for adipose tissue removal and lumen rinsing. The adventitia was enzymatically removed by incubation of the vessels in collagenase solution of MEM-α containing GlutaMAXTM (2 ml), collagenase type 1 A (0.7 mg/ml), soybean trypsin inhibitor (50 mg/ml), and bovine serum albumin (1 mg/ml) for approx. 10–20 min at 37 °C. Once the adventitia became lose, it was carefully removed as an intact layer using forceps under a dissecting microscope. The aorta was divided into aortic arch (AA) and thoracic aorta (TA) regions and cut into 1 mm pieces and digested with Elastase type III (Sigma) at 37 °C. Dispersed cells were centrifuged and washed twice in warm maintenance medium (MM) (DMEM supplemented with 2% chick embryo extract, 1% FBS, 0.02 µg/ml, bFGF basic protein, B-27 Supplement, N-2 supplement, 1% Penicillin-Streptomycin, 50 nM 2-Mercaptoethanol, and 100 nM retinoic acid) before seeding (1st seeding) on a 6-well non-adherent plate in MM. At 48 h, suspension cells were transferred (2nd seeding) to a fresh well of a CELLstart™ pre-coated 6-well plate in MM. Additional MM was added to the remaining cells in the non-adherent surface. Cells were incubated at 37 °C, 5% CO2 for 1 week with minimal disturbance. The stem cells exhibited a uniform neural-like morphology in low density culture adopting a dendritic-like tree shape and retaining their morphological characteristics at low density throughout repeated passage. Cells were fed with MM every 2–3 days and passaged every 3–4 days or when ~70% confluent.
Generation of human neuroectoderm progenitors (NEPs) from induced pluripotent stem cells (HiPSCs)
Human induced pluripotent stem cells (HiPSC) were obtained from HipSci (Cambridge, UK) and cultured per the manufacturer’s instructions. Briefly, human dermal fibroblasts were isolated from excess skin of patients undergoing plastic surgery and reprogrammed as previously described87. HiPSCs were grown on plates pre-coated using Vitronectin (10 μg/ml) and maintained in complete Essential eight medium replacing 95% of the medium daily. A ROCK inhibitor (10 µM) was added to optimize colony growth. Cells were subcultured with 0.05 mM EDTA for 4–8 min at room temperature until colonies displayed bright halos around the edges and small holes appeared throughout. Cells were frozen down in knockout serum solution with 10% DMSO. HiPSCs at 70% confluency were routinely split at a ratio of 1:10 and cells were used between passage 20–40.
For neuroectoderm differentiation, cells were grown in chemically defined neuroectodermal medium (CDM) containing IMDM, F12 nutrient mix, chemically defined lipid concentrate, transferrin, monothioglycerol, penicillin-streptomycin and 0.5 g of PVA, and insulin, as previously described43. Neuroectoderm differentiation was initiated in CDM supplemented with FGF2 (12 ng/ml) and SB431542 (10 µM) for 7 days. Neuroectodermal (NE) progenitors were maintained in CDM-PVA supplemented with FGF2 (12 ng/ml) and SB431542 (10 µM) and subcultured using TrypLE™ for 3–5 min at 37 °C in a 5% CO2 incubator. NE progenitors were used between passage 1–10.
To initiate myogenic SMC differentiation, NEPs were subcultured in SMC differentiation medium containing CDM+ PDGF-BB (10 ng/ml, PeproTech) + TGF-β1 (2 ng/ml, PeproTech) for 12 days. Neuroectoderm-derived SMCs (NE-SMC) were maintained in CDM supplemented with 10% FBS. After 12 d of PDGF-BB and TGF-β1 treatment, all cells appeared spindle-shaped. Complete medium was then changed to DMEM 10% FBS, 1% Penicillin-streptomycin for expansion. Cells were frozen down using 90% (volume/volume) FBS+ 10% (vol/vol) DMSO. The NE-SMC were used between passage 3–20.
Human tissue
Tissue sections from paired normal human aorta and arteriosclerotic vessels were obtained from Amsbio LLC, tissue repository.
Chromatin immunoprecipitation
ChIP was performed on cultured cells as previously described with slight modifications79. Cells at 70% confluency were fixed with 1% paraformaldehyde (10 min, RT). Cross-link was stopped by addition of 125 mM glycine for 10 min. The cross-linked chromatin was sonicated to shear chromatin into fragments of 200–600 base pairs. The sheared chromatin was immunoprecipitated with 2 μg tri-methyl-histone H3 (Lys27) and di-methyl-histone H3 (Lys4), while negative control was incubated with mouse IgG and input DNA without antibody using the CHIP—IT Express HT Kit from Active Motif (Cat no: 53018) according to the manufacturer’s instructions [Supplementary Table III]. A chromatin IP DNA Purification Kit (Cat No 58002 Active Motif) was used to purify the samples after CHIP before PCR was performed using Myh11 primers [5’ -CCC TCC CTT TGC TAA ACA CA–3’ and 5’ - CCA GAT CCT GGG TCC TTA CA–3]. Sensimix SYBR® no-ROX Bioline Kit (QT650) was used to perform Real Time One-Step PCR according to the manufacturers’ instructions. The antibodies used for ChIP are outlined in Supplemental Table I.
Quantitative PCR
Total RNA was prepared from cultured cells using the ReliaPrep™ RNA Cell Miniprep System kit from Promega according to the manufacturer’s protocol. Two micrograms of RNA was used for reverse transcription with Rotor-Gene SYBR Green RT-PCR (QIAGEN) or The SensiMix™ SYBR® No-ROX (BioLine) protocols for Real TimeOne-Step RT-PCR using the Real Time Rotor-GeneRG-3000™ light cycler from Corbett Research using primers listed in Supplementary Table IV.
Flow cytometry and analysis
Isolated cells were incubated with I fluorochrome-conjugated antibodies and control IgG’s or (ii) the appropriate primary antibody with fluorochrome-conjugated secondary antibodies at a final concentration of 1 μg per sample and incubated at 4 °C for 30 min [Supplementary Table V]. Fluorescence labeled cells analysis was performed using a BD FACS Aria flow cytometry system (BD Biosciences), and data were analyzed with FlowJo™ software (Tree Star, Ashland, Ore) and De Novo software FCS Express 4 Flow Cytometry (Pasadena, CA).
Telomere assay
The average telomere length in cells was measured using a ScienCell’s Absolute Mouse Telomere Length Quantification qPCR Assay Kit (AMTLQ) according to the manufacturer’s instructions. The telomere primer set recognizes and amplifies telomere sequences and is designed to directly measure the average telomere length of murine cells.
Quantification and statistical analysis
All data were determined from multiple individual biological samples and presented as mean values ± standard error of the mean (SEM). All in vitro experiments were performed in triplicate and repeated three times unless otherwise stated. All mice were randomly assigned to groups (including both male and female), and the analysis was performed blind by two groups. For statistical comparisons, all data were checked for normal gaussian distribution before parametric and non-parametric tests were performed. An unpaired two-sided Student’s t-test was performed using GraphPad Prism software v9™ for comparing differences between two groups, and ANOVA test for over multiple comparisons. Significance was accepted when p ≤ 0.05.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We thank Diana Scott for histological tissue processing, and Drs. Linda Callahan and Paivi Jordan for confocal microscope expertise. This research was funded in part by Science Foundation Ireland grant SFI-11/PI/1128, Health Research Board (HRB) of Ireland grant HRA-POR-2015-1315, the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB) to P.A.C., and NIH R21AA020365 and R21AA023213 to E.M.R., Irish Research Council (IRC) GOIPG/2014/43 (M.D.L.) and GOIPG/2016/1529 (E.C.), King Abdulla Scholarship IR15208 ID1066336148 to Y.G.
Author contributions
E.F., W.L., and J.-C.H., performed the animal experiments and M.D.L. and S.H. performed the blind analysis of the images. E.F. performed the human arteriosclerotic tissue analysis. E.F., M.D.L., R.H., D.B., and E.C., performed the murine and rat cell culture experiments, D.B. performed the HiPSCs cell work. E.C. performed the telomere assay and R.H.J, M.d.L., and Y.G. performed the ChIP analysis. E.M.R., C.L., and P.A.C. drafted the manuscript, revised the manuscript, and discussed the results. E.M.R. and P.A.C. designed and coordinated the experiments, interpreted the data, revised, and confirmed the paper. All authors reviewed and confirmed the manuscript.
Data availability
The data, materials, and reagents generated or analysed that support the findings of this study are available from the corresponding authors (P.A.C. and E.M.R.) on reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These author contributed equally: Mariana Di Luca, Emma Fitzpatrick, Denise Burtenshaw, Weimin Liu.
These authors jointly supervised this work: Eileen M. Redmond, Paul A. Cahill.
Supplementary information
The online version contains supplementary material available at 10.1038/s41536-021-00120-8.
References
- 1.Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 2016;118:692–702. doi: 10.1161/CIRCRESAHA.115.306361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Sakamoto A, et al. Pathologic intimal thickening: are we any closer to understand early transitional plaques that lead to symptomatic disease? Atherosclerosis. 2018;274:227–229. doi: 10.1016/j.atherosclerosis.2018.04.033. [DOI] [PubMed] [Google Scholar]
- 3.Halcox JPJ, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation. 2009;119:1005–1012. doi: 10.1161/CIRCULATIONAHA.108.765701. [DOI] [PubMed] [Google Scholar]
- 4.Sinha S, Iyer D, Granata A. Embryonic origins of human vascular smooth muscle cells: implications for in vitro modeling and clinical application. Cell. Mol. Life Sci. 2014;71:2271–2288. doi: 10.1007/s00018-013-1554-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Korshunov VA, Berk BC. Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler. Thromb. Vasc. Biol. 2003;23:2185–2191. doi: 10.1161/01.ATV.0000103120.06092.14. [DOI] [PubMed] [Google Scholar]
- 6.Liu W, Redmond EM, Morrow D, Cullen JP. Differential effects of daily-moderate versus weekend-binge alcohol consumption on atherosclerotic plaque development in mice. Atherosclerosis. 2011;219:448–454. doi: 10.1016/j.atherosclerosis.2011.08.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nam D, et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2009;297:H1535–H1543. doi: 10.1152/ajpheart.00510.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chappell J, et al. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. Circ. Res. 2016;119:1313–1323. doi: 10.1161/CIRCRESAHA.116.309799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Dobnikar L, et al. Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels. Nat. Commun. 2018;9:4567. doi: 10.1038/s41467-018-06891-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yuan F, et al. Contribution of vascular cells to neointimal formation. PLoS ONE. 2017;12:e0168914. doi: 10.1371/journal.pone.0168914. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Tang J, et al. Arterial Sca1+ vascular stem cells generate de novo smooth muscle for artery repair and regeneration. Cell Stem Cell. 2020;26:81–96.e4. doi: 10.1016/j.stem.2019.11.010. [DOI] [PubMed] [Google Scholar]
- 12.Tang Z, et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat. Commun. 2012;3:875. doi: 10.1038/ncomms1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kramann R, et al. Adventitial MSC-like cells are progenitors of vascular smooth muscle cells and drive vascular calcification in chronic kidney disease. Cell Stem Cell. 2016;19:628–642. doi: 10.1016/j.stem.2016.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Majesky MW, et al. Differentiated smooth muscle cells generate a subpopulation of resident vascular progenitor cells in the adventitia regulated by Klf4. Circ. Res. 2017;120:296–311. doi: 10.1161/CIRCRESAHA.116.309322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wan M, et al. Injury-activated transforming growth factor β controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells. 2012;30:2498–2511. doi: 10.1002/stem.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Donato R, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta. 2009;1793:1008–1022. doi: 10.1016/j.bbamcr.2008.11.009. [DOI] [PubMed] [Google Scholar]
- 17.Cao T, et al. S100B promotes injury-induced vascular remodeling through modulating smooth muscle phenotype. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863:2772–2782. doi: 10.1016/j.bbadis.2017.07.002. [DOI] [PubMed] [Google Scholar]
- 18.Sagheddu R, et al. Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy. Hum. Mol. Genet. 2018;27:3734–3746. doi: 10.1093/hmg/ddy288. [DOI] [PubMed] [Google Scholar]
- 19.Zhou S, Zhu W, Zhang Y, Pan S, Bao J. S100B promotes microglia M1 polarization and migration to aggravate cerebral ischemia. Inflamm. Res. 2018;67:937–949. doi: 10.1007/s00011-018-1187-y. [DOI] [PubMed] [Google Scholar]
- 20.Wu Y, et al. S100B is required for maintaining an intermediate state with double-positive Sca-1+ progenitor and vascular smooth muscle cells during neointimal formation. Stem Cell Res. Ther. 2019;10:294. doi: 10.1186/s13287-019-1400-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141:3445–3457. doi: 10.1242/dev.083691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the hedgehog receptor. Nature. 1996;384:176–179. doi: 10.1038/384176a0. [DOI] [PubMed] [Google Scholar]
- 23.Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 2013;14:416–429. doi: 10.1038/nrm3598. [DOI] [PubMed] [Google Scholar]
- 24.Marigo V, Tabin CJ. Regulation of patched by Sonic hedgehog in the developing neural tube. Proc. Natl Acad. Sci. USA. 1996;93:9346–9351. doi: 10.1073/pnas.93.18.9346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Marigo V, Johnson RL, Vortkamp A, Tabin CJ. Sonic hedgehog differentially regulates expression of GLI and GLI3 during limb development. Dev. Biol. 1996;180:273–283. doi: 10.1006/dbio.1996.0300. [DOI] [PubMed] [Google Scholar]
- 26.Chuang PT, McMahon AP. Vertebrate hedgehog signalling modulated by induction of a hedgehog- binding protein. Nature. 1999;397:617–621. doi: 10.1038/17611. [DOI] [PubMed] [Google Scholar]
- 27.Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 2011;43:333–338. doi: 10.1038/ng.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Aravani D, et al. HHIPL1, a gene at the 14q32 coronary artery disease locus, positively regulates Hedgehog signaling and promotes atherosclerosis. Circulation. 2019;140:500–513. doi: 10.1161/CIRCULATIONAHA.119.041059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Beckers L, et al. Disruption of hedgehog signalling in ApoE - /- mice reduces plasma lipid levels, but increases atherosclerosis due to enhanced lipid uptake by macrophages. J. Pathol. 2007;212:420–428. doi: 10.1002/path.2193. [DOI] [PubMed] [Google Scholar]
- 30.Ali H, et al. Localization and characterization of a novel secreted protein, SCUBE2, in the development and progression of atherosclerosis. Kobe J. Med. Sci. 2013;59:E122–E131. [PubMed] [Google Scholar]
- 31.Dutzmann J, et al. Sonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation. Cardiovasc. Res. 2017;113:1653–1663. doi: 10.1093/cvr/cvx158. [DOI] [PubMed] [Google Scholar]
- 32.Morrow D, et al. Sonic Hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A. Arterioscler. Thromb. Vasc. Biol. 2009;29:1112–1118. doi: 10.1161/ATVBAHA.109.186890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Li F, et al. Sonic hedgehog signaling induces vascular smooth muscle cell proliferation via induction of the G1 cyclin-retinoblastoma axis. Arterioscler. Thromb. Vasc. Biol. 2010;30:1787–1794. doi: 10.1161/ATVBAHA.110.208520. [DOI] [PubMed] [Google Scholar]
- 34.Wang G, et al. Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia. Biochim. Biophys. Acta. 2010;1803:1359–1367. doi: 10.1016/j.bbamcr.2010.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Passman JN, et al. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc. Natl Acad. Sci. USA. 2008;105:9349–9354. doi: 10.1073/pnas.0711382105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Shikatani EA, et al. c-Myb regulates proliferation and differentiation of adventitial Sca1+ vascular smooth Muscle cell progenitors by transactivation of myocardin. Arterioscler. Thromb. Vasc. Biol. 2016;36:1367–1376. doi: 10.1161/ATVBAHA.115.307116. [DOI] [PubMed] [Google Scholar]
- 37.Tsai T-N, et al. Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am. J. Pathol. 2012;181:362–373. doi: 10.1016/j.ajpath.2012.03.021. [DOI] [PubMed] [Google Scholar]
- 38.Fitzpatrick E, et al. Alcohol reduces arterial remodeling by inhibiting sonic Hedgehog-stimulated stem cell antigen-1 positive progenitor stem cell expansion. Alcohol. Clin. Exp. Res. 2017;41:2051–2065. doi: 10.1111/acer.13499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Redmond EM, et al. Inhibition of patched-1 prevents injury-induced neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 2013;33:1960–1964. doi: 10.1161/ATVBAHA.113.301843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Fang Y, Wu D, Birukov KG. Mechanosensing and mechanoregulation of endothelial cell functions. Compr. Physiol. 2019;9:873–904. doi: 10.1002/cphy.c180020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Reinert RB, et al. Tamoxifen-induced Cre-loxP recombination is prolonged in Pancreatic Islets of adult mice. PLoS ONE. 2012;7:e33529. doi: 10.1371/journal.pone.0033529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kennedy E, et al. Embryonic rat vascular smooth muscle cells revisited—a model for neonatal, neointimal SMC or differentiated vascular stem cells? Vasc. Cell. 2014;6:6. doi: 10.1186/2045-824X-6-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Cheung C, Bernardo AS, Trotter MWB, Pedersen RA, Sinha S. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat. Biotechnol. 2012;30:165–173. doi: 10.1038/nbt.2107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am. J. Pathol. 1997;151:697–705. [PMC free article] [PubMed] [Google Scholar]
- 45.Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat. Rev. Cardiol. 2019;16:727–744. doi: 10.1038/s41569-019-0227-9. [DOI] [PubMed] [Google Scholar]
- 46.Gomez D, Owens GK. Reconciling smooth muscle cell oligoclonality and proliferative capacity in experimental atherosclerosis. Circ. Res. 2016;119:1262–1264. doi: 10.1161/CIRCRESAHA.116.310104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hoglund VJ, Dong XR, Majesky MW. Neointima formation: a local affair. Arterioscler. Thromb. Vasc. Biol. 2010;30:1877–1879. doi: 10.1161/ATVBAHA.110.211433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Nguyen AT, et al. Smooth muscle cell plasticity: fact or fiction? Circ. Res. 2013;112:17–22. doi: 10.1161/CIRCRESAHA.112.281048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Campbell JH, Campbell GR. Smooth muscle phenotypic modulation—a personal experience. Arterioscler. Thromb. Vasc. Biol. 2012;32:1784–1789. doi: 10.1161/ATVBAHA.111.243212. [DOI] [PubMed] [Google Scholar]
- 50.Cooley BC, et al. TGF- signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci. Transl. Med. 2014;6:227ra34–227ra34. doi: 10.1126/scitranslmed.3006927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Nemenoff RA, et al. SDF-1α induction in mature smooth muscle cells by inactivation of PTEN is a critical mediator of exacerbated injury-induced neointima formation. Arterioscler. Thromb. Vasc. Biol. 2011;31:1300–1308. doi: 10.1161/ATVBAHA.111.223701. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Herring B, Hoggatt AM, Burlak C, Offermanns S. Previously differentiated medial vascular smooth muscle cells contribute to neointima formation following vascular injury. Vasc. Cell. 2014;6:21. doi: 10.1186/2045-824X-6-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Shankman LS, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat. Med. 2015;21:628–637. doi: 10.1038/nm.3866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found. Symp. 2007;283:174–191. doi: 10.1002/9780470319413.ch14. [DOI] [PubMed] [Google Scholar]
- 55.Chakraborty R, et al. Promoters to study vascular smooth muscle. Arterioscler. Thromb. Vasc. Biol. 2019;39:603–612. doi: 10.1161/ATVBAHA.119.312449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Murgai M, et al. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat. Med. 2017;23:1176–1190. doi: 10.1038/nm.4400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Sheikh AQ, Lighthouse JK, Greif DM. Recapitulation of developing artery muscularization in pulmonary hypertension. Cell Rep. 2014;6:809–817. doi: 10.1016/j.celrep.2014.01.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Roostalu U, et al. Distinct cellular mechanisms underlie smooth muscle turnover in vascular development and repair. Circ. Res. 2018;122:267–281. doi: 10.1161/CIRCRESAHA.117.312111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Tobin SW, et al. Dual roles for bone marrow–derived Sca-1 cells in cardiac function. FASEB J. 2017;31:2905–2915. doi: 10.1096/fj.201601363RR. [DOI] [PubMed] [Google Scholar]
- 60.Tang Z, Wang A, Wang D, Li S. Smooth muscle cells: to be or not to be? Response to Nguyen et Al. Circ. Res. 2013;112:23–26. doi: 10.1161/CIRCRESAHA.112.281055. [DOI] [PubMed] [Google Scholar]
- 61.Kalluri AS, et al. Single-cell analysis of the normal mouse aorta reveals functionally distinct endothelial cell populations. Circulation. 2019;140:147–163. doi: 10.1161/CIRCULATIONAHA.118.038362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Psaltis PJ, et al. Characterization of a resident population of adventitial macrophage progenitor cells in postnatal vasculature. Circ. Res. 2014;115:364–375. doi: 10.1161/CIRCRESAHA.115.303299. [DOI] [PubMed] [Google Scholar]
- 63.Hu Y, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J. Clin. Invest. 2004;113:1258–1265. doi: 10.1172/JCI19628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Wang Y-L, Liu L-Z, He Z-H, Ding K-H, Xue F. Phenotypic transformation and migration of adventitial cells following angioplasty. Exp. Ther. Med. 2012;4:26–32. doi: 10.3892/etm.2012.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Wong LCY, Langille BL. Developmental remodeling of the internal elastic lamina of rabbit arteries. Circ. Res. 1996;78:799–805. doi: 10.1161/01.RES.78.5.799. [DOI] [PubMed] [Google Scholar]
- 66.Guo Z-Y, Yan Z-Q, Bai L, Zhang M-L, Jiang Z-L. Flow shear stress affects macromolecular accumulation through modulation of internal elastic lamina fenestrae. Clin. Biomech. 2008;23:S104–S111. doi: 10.1016/j.clinbiomech.2007.08.017. [DOI] [PubMed] [Google Scholar]
- 67.Campbell GJ, Roach MR. Fenestrations in the internal elastic lamina at bifurcations of human cerebral arteries. Stroke. 1981;12:489–496. doi: 10.1161/01.STR.12.4.489. [DOI] [PubMed] [Google Scholar]
- 68.Chen Q, et al. Genetic lineage tracing analysis of c-kit+ stem/progenitor cells revealed a contribution to vascular injury-induced neointimal lesions. J. Mol. Cell. Cardiol. 2018;121:277–286. doi: 10.1016/j.yjmcc.2018.07.252. [DOI] [PubMed] [Google Scholar]
- 69.Skelly CL, Chandiwal A, Vosicky JE, Weichselbaum RR, Roizman B. Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow. Proc. Natl Acad. Sci. USA. 2007;104:12474–12478. doi: 10.1073/pnas.0705429104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Moonen J-RAJ, et al. Endothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress. Cardiovasc. Res. 2015;108:377–386. doi: 10.1093/cvr/cvv175. [DOI] [PubMed] [Google Scholar]
- 71.Souilhol C, Harmsen MC, Evans PC, Krenning G. Endothelial–mesenchymal transition in atherosclerosis. Cardiovasc. Res. 2018;114:565–577. doi: 10.1093/cvr/cvx253. [DOI] [PubMed] [Google Scholar]
- 72.Pan L, et al. Shear stress induces human aortic endothelial cell apoptosis via interleukin‑1 receptor‑associated kinase 2‑induced endoplasmic reticulum stress. Mol. Med. Rep. 2017;16:7205–7212. doi: 10.3892/mmr.2017.7524. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Heo K-S, et al. PKCζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J. Cell Biol. 2011;193:867–884. doi: 10.1083/jcb.201010051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Dong G, et al. Low shear stress-induced autophagy alleviates cell apoptosis in HUVECs. Mol. Med. Rep. 2017;15:3076–3082. doi: 10.3892/mmr.2017.6401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Zhang Y, et al. Protective effect of irisin on atherosclerosis via suppressing oxidized low density lipoprotein induced vascular inflammation and endothelial dysfunction. PLoS ONE. 2016;11:e0158038. doi: 10.1371/journal.pone.0158038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Franck G, et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion. Circ. Res. 2017;121:31–42. doi: 10.1161/CIRCRESAHA.117.310694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Bentzon JF, Majesky MW. Lineage tracking of origin and fate of smooth muscle cells in atherosclerosis. Cardiovasc. Res. 2018;114:492–500. doi: 10.1093/cvr/cvx251. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ. Res. 2018;122:433–443. doi: 10.1161/CIRCRESAHA.117.312086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Gomez D, Shankman LS, Nguyen AT, Owens GK. Detection of histone modifications at specific gene loci in single cells in histological sections. Nat. Methods. 2013;10:171–177. doi: 10.1038/nmeth.2332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Fernandez-L A, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23:2729–2741. doi: 10.1101/gad.1824509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Queiroz KCS, et al. Dichotomy in Hedgehog signaling between human healthy vessel and atherosclerotic plaques. Mol. Med. 2012;18:1122–1127. doi: 10.2119/molmed.2011.00250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Dunaeva M, van Oosterhoud C, Waltenberger J. Expression of Hedgehog signaling molecules in human atherosclerotic lesions: an autopsy study. Int. J. Cardiol. 2015;201:462–464. doi: 10.1016/j.ijcard.2015.07.091. [DOI] [PubMed] [Google Scholar]
- 83.Felley-Bosco E, Stahel R. Hippo/YAP pathway for targeted therapy. Transl. Lung Cancer Res. 2014;3:75–83. doi: 10.3978/j.issn.2218-6751.2014.02.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Cotton JL, et al. YAP/TAZ and Hedgehog coordinate growth and patterning in gastrointestinal mesenchyme. Dev. Cell. 2017;43:35–47.e4. doi: 10.1016/j.devcel.2017.08.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Ma X, Robin C, Ottersbach K, Dzierzak E. The Ly6A Sca1 GFP transgene is expressed in all adult mouse hematopoietic. Stem Cells Stem Cells. 2002;20:514–521. doi: 10.1634/stemcells.20-6-514. [DOI] [PubMed] [Google Scholar]
- 86.Van Den Brink GR, et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology. 2001;121:317–328. doi: 10.1053/gast.2001.26261. [DOI] [PubMed] [Google Scholar]
- 87.Vallier L, et al. Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent. Stem Cells Stem Cells. 2009;27:2655–2666. doi: 10.1002/stem.199. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data, materials, and reagents generated or analysed that support the findings of this study are available from the corresponding authors (P.A.C. and E.M.R.) on reasonable request.